US 12,728,107 B2
Sirtuin activator, and method for activating sirtuin
Tetsuji Noda, Tokyo (JP); Tomotsune Onaga, Tokyo (JP); and Yoshinori Katakura, Fukuoka (JP)
Assigned to Yuki Gosei Kogyo Co., Ltd., Tokyo (JP); and Kyushu University, National University Corporation, Fukuoka (JP)
Appl. No. 18/041,730
Filed by Yuki Gosei Kogyo Co., Ltd., Tokyo (JP); and Kyushu University, National University Corporation, Fukuoka (JP)
PCT Filed Aug. 18, 2021, PCT No. PCT/JP2021/030165
§ 371(c)(1), (2) Date May 9, 2023,
PCT Pub. No. WO2022/039190, PCT Pub. Date Feb. 24, 2022.
Claims priority of application No. 2020-138157 (JP), filed on Aug. 18, 2020.
Prior Publication US 2023/0310355 A1, Oct. 5, 2023
Int. Cl. A61K 31/197 (2006.01); A61P 17/00 (2006.01); A61P 21/00 (2006.01)
CPC A61K 31/197 (2013.01) [A61P 17/00 (2018.01); A61P 21/00 (2018.01)] 11 Claims
 
1. A method of activating sirtuin, comprising administering to a subject in need thereof an effective amount of β-alanine or a salt thereof, such that sirtuin is activated in said subject, wherein said method excludes medical treatment of a human subject.